Email ID
Password
Business - Strategy
EVENTS
11 March 2010
Cambridge, UK
17 March 2010
Berlin, Germany
17 March 2010
Berlin, Germany
JOB OF THE WEEK Promote your vacancy here
Slovakia’s association of research-based pharmaceutical companies (SAFS) has elected a new board. Dr Pavol Trnovec of GlaxoSmithKline, who was previously its vice-chairman, will lead SAFS as chairman. He replaces Dr Miroslav Lednar of ...
The US FDA recognises emerging and pandemic threats – and it aims to boost the development of cell-based viral vaccines with the publication of a final guidance entitled Guidance for Industry: Characterization and Qualification of Cell Substrates ...
Lilly expects its Japanese business to grow by double digits this year and has assured that it is on track to virtually double its sales in the country to more than $2 billion in 2014. "We have full confidence that we will meet our targets, which ...
GlaxoSmithKline, which has yet to decide on whether or not to participate in UNITAID 's AIDS medicines patent pool, sees more value in its own licensing approach for HIV/AIDS drugs at present. GSK chief executive Andrew Witty , who was in India to ...
Ark Therapeutics has withdrawn the EU filing of its brain cancer gene therapy candidate Cerepro (sitimagene ceradenovec), dropping a previous appeal over a negative opinion from the CHMP. It has at the same time initiated a full strategic review of ...
 
Hospitals' failure to pay pharmaceutical companies and newly announced price cuts are just some of the challenges facing the sector in Greece, Elizabeth Sukkar, Scrip's world editor, discovers. ...
The pharmaceutical industry has long eyed Turkey as one of its key emerging markets, but recent government action, which could see medicine access delayed by years, is giving it a wake-up call, ...
US agencies are making inroads in the use of comparative effectiveness research to support more robust decision-making. Observational studies are an emerging force in this area and promise to ...
 
Jeff George took over as head of Sandoz, Novartis's generics business, in late 2008. With a big push in emerging markets, a leadership position in biosimilars and an expanded focus on injectables, he ...
Developing relationships with medicine regulators in China and India is just one of the challenges facing Emer Cooke, the international face of the European Medicines Agency (EMA), Scrip's Elizabeth ...
At last year's Bio-Europe Spring conference, Trophos 's CEO Dr Damian Marron told Scrip that the French company had high hopes for its lead product TRO19622 (olesoxime) in amyotrophic lateral ...
 
Private investments began 2010 in a much more positive fashion than at the start of 2009, but were still down on the strong finish to last year, a Scrip analysis has found. A total of 15 companies ...
Emerging markets are a popular topic at the moment, with pharma firms seeking sales growth outside the mature and slowing markets of the west. There are some companies with a long history of ...
1. risk aversion converges with focus on quality The rise and rise of the biotech sector and big pharma's increasing reliance on biological products as sources of future innovation are well ...
 
Background: The renin-angiotensin-aldosterone system (RAAS) is essential for the regulation of blood pressure and may play a critical role in the pathogenesis of cardiovascular diseases. A strong ...
Increasing research interest in the new and unusual properties of nanotechnology-related pharmaceuticals and medical devices has led to international and national reviews of safety regulation. ...
Background: Introduction of highly active antiretroviral therapy has led to a profound reduction in human immunodeficiency virus (HIV) related mortality; although, the complete eradication of the ...
 
COMPANY/ORGANISATION
CONDITION
GEOGRAPHY
DRUG
© 2010 Informa plc. All rights reserved.
This site is owned and operated by Informa plc ("Informa") whose registered office is Mortimer House, 37-41 Mortimer Street, London, W1T 3JH. Registered in England and Wales. Number 3099067. UK VAT Group: GB 365 4626 36